A5052991027- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Immune cells in cancer
- CAR-T cell therapy research
- Inflammatory mediators and NSAID effects
- Glioma Diagnosis and Treatment
- Immune Response and Inflammation
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Animal testing and alternatives
- Multiple Sclerosis Research Studies
- Tryptophan and brain disorders
- Stress Responses and Cortisol
- Radiopharmaceutical Chemistry and Applications
- Cancer, Stress, Anesthesia, and Immune Response
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Immune responses and vaccinations
- Chemokine receptors and signaling
- Multiple and Secondary Primary Cancers
- Cell death mechanisms and regulation
- Circadian rhythm and melatonin
- Cancer Research and Treatments
Hospital Clínic de Barcelona
2018-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2016-2025
Radboud University Nijmegen
2018-2025
Radboud University Medical Center
2018-2025
Radboud Institute for Molecular Life Sciences
2018-2024
University Medical Center
2020-2024
Zero to Three
2021
Universitat de Barcelona
2018
Significance Application of antigen-specific immune tolerance in autoimmune disease is a long-sought goal. We studied diseases with abundant information on the target: multiple sclerosis (MS), various myelin antigens are known targets T cells and antibodies, whereas neuromyelitis optica (NMO), aquaporin-4 channel attacked by antibodies. tested whether engineered dendritic might induce tolerogenic response these two conditions. In this in-human clinical study, individual regulatory cells,...
The human dendritic cell (DC) family has recently been expanded by CD1c+CD14+CD163+ DCs, introduced as DC3s. DC3s are found in tumors and peripheral blood of cancer patients. Here, we report elevated frequencies CD14+ cDC2s, which restore to normal after tumor resection, non-small lung These cDC2s phenotypically resemble exhibit increased PD-L1, MERTK, IL-10, IDO expression, consistent with inferior T activation ability compared CD14− cDC2s. In melanoma patients undergoing CD1c+ DC...
Plasmacytoid dendritic cells (pDCs) and type 2 conventional (cDC2s) are currently under evaluation for use in cancer vaccines. Although both DC subsets can activate adaptive innate lymphocytes, their capacity to recruit such is rarely considered. Here, we show that pDCs cDC2s display a striking difference chemokine secretion, which correlates with the recruitment of distinct types immune effector cells. Activated express high levels CXCR3 ligands attract more CD8+ T cells, CD56+ γδ vitro,...
This article is part of the Dendritic Cell Guidelines series, which provides a collection state-of-the-art protocols for preparation, phenotype analysis by flow cytometry, generation, fluorescence microscopy, and functional characterization mouse human dendritic cells (DC) from lymphoid organs various non-lymphoid tissues. with top ticks pitfalls preparation successful generation DC different cellular sources, such as murine BM HoxB8 cells, well CD34+ cord blood, BM, peripheral blood or...
Cancer immunotherapies have induced long-lasting responses in cancer patients including those with melanoma and head neck squamous cell carcinoma (HNSCC). However, the majority of treated does not achieve clinical benefit from immunotherapy because systemic tumor-induced immunosuppression. Monocytic myeloid-derived suppressor cells (M-MDSCs) are implicated as key players inhibiting anti-tumor immune their frequencies closely associated tumor progression. Tumor-derived signals, signaling via...
Imbalanced immune responses are a prominent hallmark of cancer and autoimmunity. Overactive as well suppressed immunological activity is evidenced to promote disease. This disbalance often driven through disrupted immunomodulation by innate myeloid cells. Myeloid cells can be overly suppressive, inhibiting protective or inactive not controlling autoreactive Understanding the mechanisms that induce drive suppressive cells, such myeloid-derived suppressor (MDSCs) tolerogenic dendritic...
Dendritic cells (DCs) play a pivotal role in orchestrating adaptive immunity response to environmental cues such as prostaglandin E2 (PGE2). Tumors are known establish microenvironment rich PGE2. Tumor-derived PGE2 is regarded mediator of regulatory features DCs, facilitating immune evasion and tumor progression. In the effects mediated through E-prostanoid receptor type 2 (EP2) EP4. While immunomodulatory signaling via EP2/4 monocyte-derived DCs (moDCs) well-established, its human blood...
Background Lynch syndrome (LS), caused by germline pathogenic variants in the mismatch repair genes, leads to high rates of frameshift-derived neopeptide (FSDN) expression due microsatellite instability (MSI). While colorectal cancer (CRC) prevention is effective, most LS-related tumors lack such strategies. Cancer vaccines targeting FSDNs offer a promising approach for immune interception LS. This study aimed identify and validate develop prevention. Methods We identified coding MS...
Dendritic cells (DCs) are key regulators of the immune system that shape T cell responses. Regulation induction by DCs may occur via intracellular enzyme indoleamine 2,3-dioxygenase 1 (IDO), which catalyzes conversion essential amino acid tryptophan into kynurenine. Here, we examined role IDO in human peripheral blood plasmacytoid (pDCs), and type 2 conventional (cDC1s cDC2s). Our data demonstrate under homeostatic conditions, is selectively expressed cDC1s. IFN-γ or TLR ligation further...
Type 1 conventional dendritic cells (cDC1s) are characterized by their ability to induce potent CD8+ T cell responses. In efforts generate novel vaccination strategies, notably against cancer, human cDC1s emerge as an ideal target deliver antigens. uniquely express XCR1, a seven transmembrane G protein-coupled receptor. Due its restricted expression and endocytic nature, XCR1 represents attractive receptor mediate antigen-delivery cDC1s. To explore tumor antigen delivery cDC1s, we used...
Tumors educate their environment to prime the occurrence of suppressive cell subsets, which enable tumor evasion and favors progression. Among these, there are myeloid-derived suppressor cells (MDSCs), presence being associated with poor clinical outcome cancer patients. Tumor-derived prostaglandin E2 (PGE2) is known mediate MDSC differentiation acquisition pro-tumor features. In myeloid cells, PGE2 signaling mediated via E-prostanoid receptor type 2 (EP2) EP4. Although role well established...
Tumor-derived prostaglandin E2 (PGE2) impairs antitumor immunity by priming suppressive functions on various immune cell types, including dendritic cells (DCs). In this way, tumors mediate DC dysfunction and hamper their antitumoral activity. PGE2 is known to modulate function via signaling through the E-type prostanoid receptor 2 (EP2) EP4. Preclinical studies have demonstrated therapeutic value of targeting EP2/4 in DCs. Ongoing phase 1 clinical trials with EP antagonists shown...
There has recently been a paradigm shift in the field of dendritic cell (DC)-based immunotherapy, where several clinical studies have confirmed feasibility and advantageousness using directly isolated human blood-derived DCs over vitro differentiated subsets. are two major DC subsets found blood; plasmacytoid (pDCs) myeloid (mDCs), both tested clinically. CD1c+ mDCs highly efficient antigen-presenting cells that ability to secrete IL-12p70, while pDCs professional IFN-α-secreting shown...
Abstract Dendritic cells (DCs) are APCs essential in regulating the immune response. PGE2, produced during inflammation, has a pivotal role maturation of DCs and, therefore, is vital for The large variety biologic functions governed by PGE2 mediated its signaling through 4 distinct E-type prostanoid (EP) receptors. Immunogenic express EP2 and EP4, which mediate signaling. However, expression function EP receptors human tolerogenic (tol-DCs), present an inhibitory phenotype, have not yet, to...
Abstract MerTK is a transmembrane receptor tyrosine kinase (RTK) mainly expressed in dendritic cells (DCs) and macrophages where it plays an important role immunotolerance, but also activating oncogenic signalling pathways. Albeit exploited as clinical target cancer auto-immune disorders, the mechanisms that regulate its diverse functions are poorly understood. Here, we identified remarkably high pool of full nucleus human DCs. Nuclear translocation was ligand-dependent. Importantly, nuclear...
Abstract Dendritic cells (DCs) are essential in antitumor immunity. In humans, three main DC subsets defined: two types of conventional DCs (cDC1s and cDC2s) plasmacytoid (pDCs). To study the tumor microenvironment (TME), it is important to correctly identify them tissues. Tumor‐derived often analyzed cell suspensions which spatial information about can be determine their function within TME lost. Therefore, we developed first standardized optimized multiplex immunohistochemistry panel,...
The STAT signaling pathway is important in dendritic cell (DC) development and function. Tumor cells can induce signaling, thereby inhibiting DC maturation immunostimulatory functions, leading to hampered efficacy of DC-based immunotherapies. Platinum-based chemotherapeutics inhibit making them an interesting tool improve In this study, we provide a comprehensive overview expression phosphorylation during differentiation investigate the effects platinum drugs on these processes. Monocytes...
Prostaglandin E2 (PGE2) is an important maturation mediator for dendritic cells (DCs). However, increased PGE2 levels in the tumor exert immunosuppressive effects on DCs by signaling through two E-Prostanoid (EP) receptors: EP2 and EP4. Blocking EP-receptor of with antagonists currently being investigated clinical applications to enhance anti-tumor immunity. In this study, we a new delivery approach encapsulating EP2/EP4 polymeric nanoparticles. The nanoparticles were characterized size,...
Dendritic cells (DCs) shape adaptive immunity in response to environmental cues such as cytokines or lipid mediators, including prostaglandin E2 (PGE2). In cancer, tumors are known establish an enriched PGE2 microenvironment. Tumor-derived primes regulatory features across immune cells, DCs, facilitating tumor progression. shapes DC function by providing signaling via its two so-called E-prostanoid receptors (EPs) EP2 and EP4. Although studies with monocyte-derived DCs have shown the...